Spyre Therapeutics (SYRE) Net Income (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Net Income came in at -$69.0 million in Q1 2026, down 54.12% YoY from -$150.4 million in Q1 2025, and down 10.36% on a QoQ basis from -$62.5 million in Q4 2025.
Spyre Therapeutics (SYRE) Net Income (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Net Income data on file, last reported at -$69.0 million in Q1 2026.
- Quarterly Net Income fell 54.12% year-over-year to -$69.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$179.4 million (up 14.12% YoY) and the FY2025 annual result came in at -$155.2 million, up 25.39% from the prior year.
- Net Income eased to -$69.0 million in Q1 2026, from -$62.5 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$11.2 million in Q3 2025 to a low of -$217.1 million in Q2 2023.
- A 5-year average of -$50.3 million and a median of -$40.1 million in 2023 frame the typical range for Net Income.
- Annual changes were most pronounced in 2023 — Net Income sank 872.45% — and 2025, when it surged 83.8%.
- Tracing SYRE's Net Income over 5 years: stood at -$18.8 million in 2022, then slumped by 235.67% to -$63.2 million in 2023, then advanced by 10.9% to -$56.3 million in 2024, then decreased by 11.07% to -$62.5 million in 2025, then dropped by 10.36% to -$69.0 million in 2026.
- The last three Net Income figures came in at -$69.0 million (Q1 2026), -$62.5 million (Q4 2025), and -$11.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | -36.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.20 Mn |
| Mar 31, 2026 | -69.01 Mn |
| Dec 31, 2025 | -62.53 Mn |
| Sep 30, 2025 | -11.18 Mn |
| Jun 30, 2025 | -36.72 Mn |
| Mar 31, 2025 | -44.77 Mn |
| Dec 31, 2024 | -56.30 Mn |
| Sep 30, 2024 | -69.03 Mn |
| Jun 30, 2024 | -38.84 Mn |
| Mar 31, 2024 | -43.86 Mn |
| Dec 31, 2023 | -63.18 Mn |
| Sep 30, 2023 | -40.11 Mn |
| Jun 30, 2023 | -217.08 Mn |
| Mar 31, 2023 | -18.42 Mn |
| Dec 31, 2022 | -18.82 Mn |
| Sep 30, 2022 | -18.23 Mn |
| Jun 30, 2022 | -22.32 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.45 Mn |
| Sep 30, 2021 | -20.31 Mn |